English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Rothia mucilaginosa  is a Gram-positive coccus and an opportunistic pathogen in immunocompromised hosts. The microorganism has been implicated in serious infections, including bacteremia meningitis or endocarditis. However, there is a dearth of investigations on meningitis, especially in children. As this infection is rare and only a few cases have been recorded, evidence-based guidelines for adequate infection treatment are lacking. We herein report the case of a 12-year-old boy with myelodysplastic syndromes (MDS) presenting with a change in mental status who was diagnosed as having febrile neutropenia and bacterial meningitis caused by  R. mucilaginosa  at 23 days after unrelated cord blood transplant. In our case, the minimum inhibitory concentrations (MICs) of meropenem and vancomycin (VCM) were both ≤1  μ g/mL, whereas the MIC of daptomycin (DAP) was 4  μ g/mL. The patient was treated with intravenous antimicrobial therapy due to meropenem for 43 days because he had febrile neutropenia. During follow-up, the patient had no neurological complications. We retrospectively reviewed the antimicrobial susceptibility of all  R. mucilaginosa  isolates ( n  = 5) from blood or cerebrospinal fluid cultures at our hospital. The MIC of VCM was <0.5  μ g/mL for all strains, whereas the MIC of DAP was ≥2  μ g/mL for all strains. The MIC of MEPM was >1  μ g/mL for one strain. We recommend choosing VCM as the primary treatment for invasive  R. mucilaginosa  infections until antimicrobial susceptibility results are known, especially in immunocompromised children.

Rothia mucilaginosa Meningitis in a Child with Myelodysplastic Syndromes